Sign in to view content

Assessment of the Inclusion of Racial/Ethnic Minorities in Retina Clinical Trials

Vivienne S. Hau, MD, PhD

Video
Published 2022

Related

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
Phase 2 Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia
Updates from the Field
2017
Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression
Carl D. Regillo, MD
Annual Meeting Talks
2018

Category: Dry AMD

See more